ZURICH, April 30 (Reuters) - Swiss generic and

biosimilar manufacturer Sandoz said on Tuesday it had

reached an agreement with U.S. drugmaker Amgen ( AMGN )

resolving all patent litigation related to its U.S. denosumab

biosimilars.

The agreement clears the way for the launch of denosumab

biosimilars Jubbonti and Wyost on May 31, 2025, or earlier under

certain circumstances, Sandoz said in a statement.

"The terms of the agreement will not impact our previously

disclosed 2024 guidance," Sandoz said.

Patent infringement proceedings were initially filed by

Amgen ( AMGN ) in the U.S. Federal District Court for the District of New

Jersey in May 2023, the statement said.

(Writing by Dave Graham

Editing by Miranda Murray)